Rouen, France, January 13, 2021 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in France – spanning 75 miles (120 km) between the two locations. The procedure is the first of its kind…

Rouen, France, December 14, 2020 — Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces that it has appointed Chantal Le Chat as an independent member of the Strategic Committee.

Chantal boasts 35 years of skill and know-how built up while working a range of posts at imaging major player GE Healthcare. Over the last six years, she has occupied key strategic roles in the company’s Interventional Division, including…

Rouen, France, November 2, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces creation of the joint venture with MicroPort Scientific Corporation ‘MicroPort’, through ‘MedBot’, its MicroPort MedBot (Shanghai) Co. Ltd subsidiary. This strategic partnership will enable the commercialization in China of its first robotic-assisted platform, R-One™. Both companies will also carry out research and development activities as agreed per the terms of the investment announced in April…

Rouen, France, April 29, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has secured €40 million ($43M) in a series C round of financing. This was led by MicroPort Scientific Corporation (HKG:853), a major listed industrial player in the cardiovascular field, with participation from institutional investors (Zhejiang Silk Road Fund, Luxembourg CLIIF managed under TUS-Holdings, CS Group and Anaxago) as well as existing Robocath investors (1).

Rouen, France, January 21, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has successfully completed its first robotic coronary angioplasties with R-One™ in Germany. The Percutaneous Coronary Interventions (PCI) were performed by Prof. Michael Haude, a recognized and highly experienced interventional cardiologist at Rheinland Klinikum Neuss Lukaskrankenhaus, and his team.  

Prof. Michael Haude, Director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, said, “I’m proud…

Rouen, France, December 16, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has successfully completed six robotic coronary angioplasties with R-One™, a first for the continent of Africa. These Percutaneous Coronary Interventions (PCI) were performed by Dr Faizel Lorgat, an interventional cardiologist at the Netcare Christiaan Barnard Memorial Hospital, Cape Town, as part of a distribution agreement with Vertice MedTechGroup. These procedures will lead to the…

The procedures were performed at Rouen University Hospital and Clinique Pasteur in Toulouse (France) and precede the first clinical study of its kind to be conducted in Europe

Rouen, September 24, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the success of its first two coronary angioplasties performed with assistance from its R-One™ robotic platform. The procedures were performed in France at Rouen University Hospital by Professor…

Rouen, September 3, 2019. – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that it has raised €5 million ($5.5M) to support the rollout of its robotic platform in strategic European target markets. The company has also hired Lucien Goffart as CEO.

With twenty years of experience in interventional cardiology, Lucien Goffart has held a number of key positions in leading companies in the sector. He also has a…

Rouen, France, May 21, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that Pr Haude, Dr Lorgat and Pr Nef have joined its medical advisory board. All are global experts and recognized leaders in interventional cardiology.

The board plays a key role in defining the clinical strategy of the company. Their clinical work will contribute to the worldwide growth of robotics in interventional cardiology.

Philippe Bencteux, president…

Rouen, France, February 26, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that it has obtained CE certification for its R-One™ robotic device. As a result, it can begin commercialization in Europe and the Middle East.

R-One™ is the first European robotic solution to obtain the CE mark in the field of interventional cardiology. The robot assists interventional cardiologists in stenting (angioplasty) by enabling precision technologies that…